Merus (NASDAQ:MRUS) Expected to Post FY2024 Earnings of ($3.66) Per Share

Merus (NASDAQ:MRUS) – Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for shares of Merus in a report issued on Wednesday, April 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn ($3.66) per share for the year, down from their prior forecast of ($3.54). The consensus estimate for Merus’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2024 earnings at ($1.09) EPS, FY2025 earnings at ($4.16) EPS and FY2026 earnings at ($0.84) EPS.

Merus (NASDAQ:MRUS) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. The business had revenue of $8.94 million during the quarter, compared to analyst estimates of $10.43 million.

Several other research firms have also issued reports on MRUS. Stifel Nicolaus upped their price target on Merus from $40.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. BMO Capital Markets upped their price target on Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of Merus in a research report on Thursday, April 11th. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on Monday, April 22nd. Finally, StockNews.com lowered Merus from a “hold” rating to a “sell” rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.33.

Merus Stock Up 0.2 %

Shares of MRUS opened at $45.04 on Monday. The business’s 50 day moving average is $45.03 and its two-hundred day moving average is $34.00. Merus has a 52-week low of $18.21 and a 52-week high of $52.03. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -14.82 and a beta of 1.10.

Institutional Investors Weigh In On Merus

Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new stake in shares of Merus during the 1st quarter valued at about $72,000. Sierra Summit Advisors LLC acquired a new stake in shares of Merus during the 4th quarter valued at about $221,000. Parkman Healthcare Partners LLC lifted its holdings in shares of Merus by 20.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 157,817 shares of the biotechnology company’s stock valued at $4,340,000 after buying an additional 27,082 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of Merus during the 4th quarter valued at about $550,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Merus during the 4th quarter valued at about $660,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.